Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Is that one day
1.50 p
2.£1
3. £8
Or is it a Genmab license platform. A share price with dividend
I have been holding a long time unfortunately my average is still underwater. Feel confident though is this
Fantastic documentation from Scancell website suggest you all have a good read ?
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/2024/scancell-interim-results-fy-2024.pdf
Maybe AstraZeneca could not afford Scancell 😂 , maybe in the long run licensing offers greater value , see Genmab expanding balance and pipeline ,
the Avidimab and Glymab platforms are very exciting . as the chairman said Yes Big pharma know of us , more data more money
The upfront cash portion of the consideration represents a transaction value of approximately $2 billion, a 97% premium to Fusion's closing market price of $10.64 on March 18, 2024, and an 85% premium to the 30-day volume-weighted average price (VWAP) of $11.37 before this announcement. Combined, the upfront and maximum potential contingent value payments represent, if achieved, a transaction value of approximately $2.4 billion, a 126% premium to Fusion's closing market price on March 18, 2024, and a 111% premium to the 30-day VWAP. As part of the transaction, AstraZeneca will acquire the cash, cash equivalents and short-term investments on Fusion's balance sheet, which totaled $234 million as of December 31, 2023.
Don't forget this overview written and presented January 2024 interim results giving a great breakdown of where we are up to
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/2024/scancell-interim-results-fy-2024.pdf
Starts today good luck to both
BIO-Europe Spring in Barcelona, Spain from 18-20 March
Mandeep Sehmi, Head of Business Development and Mireille Vankemmelbeke, PI at Scancell will be attending the conference.
Markus 2 other side interesting points :
Avidimab explained well. It could improve and potentially extend patent life for big Pharma products. In 2022 Trinity thought Avidimab could have peak sales of £8.5 billion and a royalty for us of 8%.
The early Scib-1 results 2018
I am thinking about the cash the Genmab have now accumulated thanks to their clever approach to their KYSO ( knock your socks off IP , some thought that wa joke ? clearly not ) Ip
Hi
I thinks it will be very quiet until the deal is done . the company is well funded with an experienced team . I imagine the suiters are lining up and as stated by the chairman , the big pharma are well aware , more data = more money , so patience is required
From Markus 2 other side . Excellent summary :
I think companies have enough info on Avidimab to make a deal. Those early assessments maybe did not proceed as the deals were too small and unattractive.
E.G.
Seagen/Pfizer tested it.
SEA-CD40 (Seagen) is in Phase II trials for advanced solid tumours. AvidiMab was
used in the Fc region (Exhibit 5) in an IgG1 format, with key residues from murine
IgG3 transferred into the human SEA-CD40 IgG1 Fc region. The results for iSEACD40 showed higher Fc-Fc self-association, slower off-rate and improved binding
to CD40, and better functional affinity than original SEA-CD40. These findings of
better performance were also seen in other immune models that rely on clustering
and/or increased residence time for activity. Preclinical work continues to
highlight the versatility and broad applicability of the AvidiMab platform, with
sizable improvements seen across many applications.
AvidiMab is employed in the COVIDITY programme, where
recent results have validated AvidiMab as an immune response booster.
Avidimab enhanced Glycans
SC88 binds to unique glycan (Lewis a/c/x) on GP and GL
h88 targets 100% of colorectal tumours on TMAs with restricted normal tissue distribution
AvidiMab TM technology introduces intermolecular cooperativity => enhanced target avidity
AvidiMab TM-engineered SC88, i88G1, exhibits inflammatory cell killing (ICD) through pore formation
SC27
AvidiMab TM engineered SC27, i27G1 exhibits improved functional affinity and direct cell killing
iSC2811
Ultraspecific SSEA4 mAb – lead AvidiMab® modified clinical candidate
iSC2811 enhances T cell engraftment and prevents exhaustion
Potential for improving CAR-T approaches
Scancell also demonstrated AvidiMab® modification of SC129 (Genmab)
reduces the off-rate
AvidiMab® – a proprietary platform for enhancing the avidity of
any antibody
► Enhances avidity by promoting Fc-Fc
interactions
► Reduces off-rate → increased affinity
► Increases direct cell-killing
► Potential to improve the therapeutic index of
any monoclonal antibody
► Patent protected
Could extend patent life.
Yes no wonder New CFO to count the money coming Royalties from a “ platform “ business
Exciting
Https://www.fiercebiotech.com/biotech/genmab-grows-celebrating-25-years-company-plans-partner-less-and-own-more
But taking a corporate leap forward will mean building out a commercial infrastructure that can sell Genmab’s products without the need to split revenue with a partner. The vast majority of Genmab’s 16.4 billion Danish kroner revenue in 2023 ($2.4 billion) came from royalties— 83% to be exact.
“That's the next phase, basically—to hold on to these molecules,” van de Winkel said. He conceded that the company may look for partners in the Global South, but that largely, Genmab wants to be independent. Van de Winkel says Genmab now has the capabilities and capital to run multiple phase 3 trials in parallel, the exact kind of investment that it would have needed a partner to help pay for in years past.
The solid financial footing also has Genmab on the acquisition hunt to further bolster the portfolio, specifically in search of molecules in later stages of development.
Heather shaw is speaking investigator and author re Scooe trial
https://melanomafocus.org/for-professionals/meetings-and-events/melanoma-focus-virtual-regional-meeting-2024/
9:15-09:45 Melanoma for 2030: A horizon scan of future options and how do we get ourselves ready
Dr Heather Shaw, Consultant Medical Oncologist, Mount Vernon Cancer Centre and UCLH
Efficacy and safety results from the open-label Phase 2 SCOPE trial.
ABSTRACT: Presentation at the 20th International Congress of the Society for Melanoma Research - Philadelphia, November 6th - 9th, 2023
Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Dennis Hadjiyiannakis, Clare Barlow, Martin Highley, Amna Sheri, Amanda Fitzpatrick, Ioannis Karydis, Maria Marples, Robert Miller, Fayaz Master and Lindy Durrant
Part 1 the full Scancell post on LinkedIn
Lucía Turnes and Georgia Goodhew from the clinical operations team at Scancell Ltd recently attended the Melanoma Focus annual meeting and share their thoughts and valuable insights. https://lnkd.in/dTxY_XdF
The meeting is geared towards #patients and carers, provides updates and information on current treatments, access and support. Supporting patient centric meetings allows us at Scancell to understand the pateint perspective and incorporate learnings into our #cancervaccine SCOPE study clinical trial designs, putting patients at the forefront of our current and future studies.
Thank you to Imogen Cheese for sharing her thoughts and recognition to all those who attended and supported the meeting.
Learn about the SCOPE study: https://lnkd.in/eivcrTxX
Find link s below
https://www.scancell.co.uk/scancell-attends-and-sponsors-the-annual-melanoma-patient-meeting
“Valuable insights from the meeting
Treatment for melanoma has come a very long way from a disease that was previously incurable when detected late to a disease that is manageable and even cured despite patients having advanced metastatic disease. Sponsors are developing treatments in all key stages of presentation of disease. Vaccines in general are gaining good momentum in both the early stages of presentation (V940-001 mRNA 4157 Merck & Moderna) and the late stages of presentation or stage migration where Scancell's SCIB1 and iSCIB1+ DNA vaccines are being tested. This is an interesting time for patients and sponsors of clinical trials as nucleic acid vaccines are being combined with checkpoint inhibitors with good early results Additionally, basic research on gut microbiome and immunotherapy was very interesting for patients, especially the correlation between antibiotic use and the impact of efficacy of checkpoint inhibitors. Going forwards this type of information will inform eligibility criteria for future studies with SCIB1 and iSCIB1+.”
Learn more about the study
https://www.scancell.co.uk/Data/Sites/1/media/fininfo/2024/scancell-interim-results-fy-2024.pdf
09:38 chilltime: Scib update all current patients.
Just for mention pre the poster event, news anticipated etc.
As previously mentioned, going by previous news updates, all patients would have had their week 25 scan by the end of January.
The passage of time and no update, has moved all patients completing the week 25 scan by mid March.
Jan 31st was the latest based on news and didn’t include, the time gap backwards to when Scancell got the data, reviewed it then released news. That probably takes 2 weeks, scan, clinic evaluation of scan inform patient, pass onto Scancell, evaluate, news etc.
So it’s likely all 25 scans are already complete a week or two ago.
So Scancell are well set to release details of all patients now all of which have had at least 3 scans.
A fair chance of news on the topic very shortly if they intend to release news.
International women’s day
Link to LinkedIn page :
https://www.linkedin.com/feed/update/urn:li:activity:7171986129829646337?updateEntityUrn=urn%3Ali%3Afs_feedUpdate%3A%28V2%2Curn%3Ali%3Aactivity%3A7171986129829646337%29
For those not on linked in I have cut and pasted the article below .
Scancell Ltd
2,113 followers
10h Edited
💫 On #internationalwomensday2024, this year’s theme is "Invest in women: Accelerate progress“. Scancell Ltd was founded by Lindy Durrant over 20 years ago and she has shared some thoughts on her journey as inspiration to other women embarking on entrepreneurship in biotech to #inspireinclusion.
Female-led start ups and women in senior positions remain less represented across the UK, USA and Europe. Startups led by women are even rarer, and women make up a similarly lower percentage of non-executive directors on boards of biotech companies, reported in an article published in Nature. At Scancell Ltd, we are proud to say women are well represented at senior levels, the board and accross our research teams.
🖥 Learn about Scancell: https://lnkd.in/eHs_3dVy
📑 Read the article: https://lnkd.in/guw6XPN5
#iwd2024womenleadingtheway #iwd2024 #womeninscience #leadership #biotechinnovation
From linked in
Our Research Scientists, Poonam Vaghela and Foram Dave, PhD, will be speaking at the OxfordGlobal Conferences UK – Biologics 2024 conference taking place from 13-15 March 2024 in London, UK. They will be discussing glycan targeting antibodies for T cell redirection and will be presenting preclinical results from reformatting GlyMab® into potential therapeutic modalities for T cell redirection.
✉ Further information: commercial.enquiries@scancell.co.uk
🔎 View the full agenda: https://lnkd.in/eWSWFCH5
#Conference #Immunotherapy #Cancer #immunooncology #immunotherapy #antibodies #antibodydrugconjugates
https://oxfordglobal.com/biologics/events/biologics-2024
This job offer Was posted by Callum Scott LinkedIn page . joined Scancell in February 5 th
Have already posted the full job description:
Here the paragraph that accompanied the advert
“Are you passionate about revolutionising cancer treatment through innovative immunotherapies? If so, then a fantastic opportunity has arisen for a CMC Regulatory Scientist to join a dynamic team which pushes the boundaries of science to make a real impact on patients' lives. We offer a collaborative and supportive environment where your contributions are valued, along with opportunities for professional growth and development. If you are ready to join a forward-thinking company dedicated to making a difference, apply now to become our next CMC Regulatory Scientist! #CMC #Biotech #Immunotherapy #RegulatoryScience”
Dr Scott brings over 15 years of experience in vaccine research and development. Previously, he held the role of Technical Transfer & Formulation Development Manager at UK biotech firm Allergy Therapeutics (AIM: AGY) where he led all CMC (Chemistry, Manufacturing and Controls)/product development activities relating to their VLP Peanut project through Phases 1-3 including IND approvals. Dr Scott holds a PhD in Molecular Microbiology and a BSc in Biochemistry, both from Heriot-Watt University.
CMC Regulatory Scientist
Location: Remote/Oxford Science Park, Permanent, Full-time
Responsible to: Head of Development / Head of Manufacturing
Company Summary
Scancell is an AIM listed biotech company developing novel immunotherapies for the treatment of cancer and infectious disease, with facilities on the Oxford Science Park and at Nottingham University.
Scancell is currently conducting a Phase 2 trial of its ImmunoBody® vaccine in melanoma patients, and a Phase 1/2 first-in-human trial of its Moditope® vaccine in patients with advanced solid tumours.
Scancell currently employs nearly 60 staff, with research scientists located in Nottingham and managerial, translational research, development and administrative staff in Oxford. Scientists working in the Company’s laboratory facilities on the Oxford Science Park support the Company’s clinical trial activities, alongside formulation and analytical development activities for its novel products.
Summary of Post
The CMC Regulatory Scientist will support product development activities, specifically the implementation of regulatory-compliant strategies. The post-holder will be responsible for the technical review and preparation of CMC documents to support regulatory submissions. An applied understanding of product development, including an ability to interpret and apply regulatory guidelines to ongoing CMC activities, is essential. The post holder will also support internal formulation development activities.
Key duties and responsibilities
Leading on the preparation and review of CMC sections relevant to regulatory submissions.
Authoring and reviewing CMC documents (i.e., manufacturing batch-records, specifications, protocols & technical reports) required to support regulatory submissions.
Subject matter expert for products under development.
Positively engage with internal and external stakeholders to ensure the completion of CMC activities required to support regulatory submissions within project timelines.
Develop, maintain, and update a product specification file (PSF).
The CMC Regulatory Scientist will work with external consultants to support the preparation of regulatory submissions.
Routinely review proposed CMC strategies to ensure compliance with the relevant regulatory authority.
Liaise with external vendors and consultants.
Review formulation data and prepare technical reports.
Attend company meetings.
Commit to continued professional development.
Follow company policies and procedures as part of a Quality Management System.
Role requirements
Essential:
An undergraduate degree in a biological or chemical subject.
An understanding of biologic product development/CMC activities (e.g., stability, formulation development, process development, analytical development & manufacturing).
Experience developing and/or manufacturing novel biologics (e.g., recombinants, peptides, and/or antibodies).
Excellent written and communication skills.
Excellent post from Marcus 2 on other board
15:30 marcusl2: 3nobody,
I am very sorry to hear about that disappointment. I am not familiar with the rest of Ultimovacs pipeline but hopefully they do well with the rest of it.
I have been here before myself and took a huge hit when Trovax failed. Only after looking at Scib-1 early success in trials and researching Scancell at length did I fully invest.
Lindy explained why early vaccines failed
Just a reminder about Scib-1;
From Prof Durrant
At this point in this space Ultimovacs is our only competitor in Melanoma and they are using doublet like us.
She thinks their vaccine is inferior as it only targets a single antigen.
That is why we have not moved forward with Scib-2 as it only targets a single antigen (NY-ESO-1) and she thinks there would be an immune escape.
She also thinks if scib/iScib+ works we will beat Moderna hands down as we are off the shelf.
Moderna has told her "if you are correct Lindy then we are in trouble"
SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. Both proteins play key roles in the production of melanin in the skin.
iScib+ adds Avidimab plus several more epitopes.
I am certainly hoping that Scancell reaches a valuation multiples of today's.
Advanced unresectable melanoma is a $1.5 billion market on its own.